Great Hill Partners Announces Strategic Growth Investment in Peter Park
MUNICH & LONDON--(BUSINESS WIRE)--Great Hill Partners, ('Great Hill'), a private equity firm that invests in high-growth, disruptive companies, today announced that it has agreed to make a majority investment in Peter Park System GmbH ('the Company'), a leading provider of digital parking solutions. Great Hill's investment will support the accelerated build-out of Peter Park's salesforce and technology, expand the Company's footprint, and help continue executing its ambitious growth strategy. As part of the investment, the family office of ARBAnova Familienstiftung will make an additional minority investment, and Maximilian Schlereth, Co-Founder and CEO of Peter Park, along with the founding management team, Patrick Bartler (COO), Stefan Schenk (CCO), and Christoph Heinle (CTO), will roll over their equity investments and continue to lead the Company. This investment in Peter Park will bring the Company's total growth financing to over €100 million to date.
Peter Park is a Munich-based technology company redefining off-street urban parking with a fully digital, frictionless platform. In a sector long constrained by analog systems, high operating costs, and inefficient revenue models, Peter Park enables customers across various industries, including retail, healthcare, and tourism, to streamline operations and increase efficiency while enhancing user experience. The Company currently has more than 450 customers and over 90,000 parking spots across Germany, Austria, Switzerland, and Italy and has achieved 274% organic, year-over-year growth since 2021, accelerating the digitization of urban mobility.
'We believe Peter Park is redefining what modern, digital parking can look like,' said Drew Loucks, Managing Director at Great Hill Partners and head of the firm's London office. 'We see a significant runway for growth in this market, and we believe Peter Park stands out from the competition with its highly sophisticated platform, seamless on-site implementation, and a truly customer-first approach. We're excited to partner with Maximilian and the Peter Park team to further their goal of turning outdated lots into connected, revenue-optimized mobility hubs.'
'As cities across Europe face growing pressure to reduce congestion and make smarter use of limited urban space, the need for scalable, digital parking infrastructure has never been more urgent,' said Schlereth. 'We're thrilled to welcome Great Hill as a value-add partner. Their proven track record of turbocharging growth through effective go-to-market strategies, deep operational expertise, and access to seasoned growth partners makes them the ideal fit for our next phase. With their support, we believe we're well-positioned to scale our salesforce, expand our footprint, and unlock new growth opportunities.'
Great Hill's investment in Peter Park will build on the Firm's recent momentum and activity across the UK and continental Europe since opening its London office in 2023. Great Hill has recently completed a number of investments in the region, including Vivup/Perkbox, BigChange and Dealfront.
About Great Hill Partners
Founded in 1998, Great Hill Partners is a private equity firm targeting investments of $100 million to $500 million in high-growth companies across the software, financial services, healthcare, consumer, and business services sectors. With offices in Boston and London, Great Hill has raised over $12 billion of commitments and invested in more than 100 companies, establishing an extensive track record of building long-term partnerships with entrepreneurs and providing flexible resources to help middle-market companies scale. Great Hill has been recognized for its industry leadership, being ranked in the top five of HEC Paris-Dow Jones' Mid-Market and Large Buyout Performance Ranking lists from 2021-2024. For more information, including a list of all Great Hill investments, please visit www.greathillpartners.com.
About Peter Park
Peter Park System GmbH is a leading provider of AI-driven digital parking infrastructure, transforming traditional parking lots into fully automated, intelligent mobility hubs. Founded in Munich in 2019, Peter Park replaces outdated systems - such as paper tickets and physical barriers - with proprietary license plate recognition (ALPR) technology and a scalable, cloud-based platform. Designed for maximum operational efficiency and minimal friction, the system enables seamless, end-to-end automation across entire parking portfolios.
Peter Park delivers a best-in-class customer experience for drivers and provides real estate owners, municipalities, airports, and healthcare facilities with centralized control, real-time analytics, and flexible monetization tools. Active in Germany, Austria, Italy, and Switzerland, the company is positioned at the forefront of the digital transformation in parking and mobility - shaping the future of how people arrive at and depart from destinations. Learn more about Peter Park here https://en.peter-park.de/.
About ARBAnova
Founded by the entrepreneurs Marianne and Reinhold Barlian in 2017, the family office of the trust invests into mid-sized companies and startups via its venture arm.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
7 minutes ago
- Time Business News
Best Electrical Services on the Sunshine Coast — Niche Electrical Group
When you're looking for dependable electrical work on the Sunshine Coast, you need a team that's experienced, licensed, and focused on safety. At Niche Electrical Group, we provide high-quality electrical services across residential, commercial, and industrial sectors — with a reputation for prompt, efficient solutions that last. From urgent electrical faults to major installations, our electricians handle every job with precision and care. Our standout offering? Specialised industrial electrical maintenance that ensures your critical systems operate safely and efficiently year-round. Why Locals Choose Niche Electrical Group As a Sunshine Coast-based company, we take pride in delivering electrical services that meet the specific needs of our local community. Our fully insured and qualified team has experience across all types of projects — from home renovations to factory fit-outs — always with a strong focus on safety, compliance, and customer satisfaction. We use the latest tools and high-quality materials to guarantee reliable results. Whether you're upgrading your home's lighting or planning a long-term industrial electrical maintenance strategy, you can count on us to get it right the first time. Electrical Services for Every Environment Residential Electrical Ensure your home is powered safely and efficiently with our full range of residential services: Custom lighting design and installs Switchboard upgrades Safety switch and smoke alarm installation Home security systems and smart automation General fault finding and compliance checks Need help fast? We also offer quick-response emergency services and preventative maintenance. Commercial Electrical Businesses need electrical systems they can rely on. We offer tailored solutions for: Shop and office fit-outs Network and data cabling LED lighting upgrades Test and tag compliance Switches, power outlets, and more Our electricians work to your schedule, delivering projects on time and within budget. The Sunshine Coast's Industrial Electrical Maintenance Experts For industrial clients, we offer complete industrial electrical maintenance services to help keep operations running without disruption. Industrial environments require robust, expertly maintained systems — and our team delivers exactly that. What Does Industrial Electrical Maintenance Involve? It's the regular servicing, repair, and inspection of electrical systems in plants, warehouses, and production facilities. We work on: Switchboards and control panels High-voltage motors and drives PLCs and automation systems Industrial lighting and HVAC Power distribution setups Emergency systems (UPS, generators) Our trained electricians ensure all work complies with WHS regulations and Australian electrical standards. Why Preventive Maintenance Matters Avoid Downtime : Catch issues early before they cause system failures : Catch issues early before they cause system failures Extend Equipment Life : Keep components running longer : Keep components running longer Boost Safety : Prevent electrical hazards with regular checks : Prevent electrical hazards with regular checks Cut Energy Waste : Identify and fix inefficiencies : Identify and fix inefficiencies Stay Compliant: Meet all local safety and wiring codes Available 24/7 for Emergency Electrical Work Power failures and unexpected issues don't follow a 9-to-5 schedule. That's why Niche Electrical Group is available around the clock to handle emergency situations. Whether it's your home, business, or industrial site, we respond fast to get things running again. Local Electricians You Can Trust We're proud to be part of the Sunshine Coast community — known for our honest advice, professional workmanship, and dedication to quality. From once-off callouts to long-term maintenance plans, Niche Electrical Group is ready to be your go-to electrical partner. Explore our full range of services and discover why more locals are turning to us for reliable industrial electrical maintenance and beyond. TIME BUSINESS NEWS
Yahoo
8 minutes ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Kaldvík AS: Mandatory notifications of trade and share lending (Update)
Frøya, Norway, 5 June 2025: Reference is made to the stock exchange announcement made by Kaldvík AS ("Kaldvík" or the "Company") earlier today (the "Announcement"), regarding the successful completion of a private placement (the "Private Placement") of new shares in the Company raising gross proceeds of approximately NOK 532 million, equal to approximately EUR 46.2 million. In connection with the Private Placement, the following transactions have been made by close associates of the Company's primary insiders: Austur Holding AS, a close associate of Lars Måsøval, a primary insider of the Company, has subscribed for 27,045,027 new shares in the Private Placement and lent shares do DNB Carnegie, a part of DNB Bank ASA ('DNB Carnegie') to facilitate settlement. AR-Invest AS, a close associate of Asle Rønning, a primary insider of the Company, has subscribed for 32,910 new shares in the Private Placement. As further described in the Announcement, the Private Placement consists of two tranches, of which tranche 1 comprises 5,976,172 offer shares ("Tranche 1") and tranche 2 comprises 32,034,878 offer shares ("Tranche 2"), the latter subject to a resolution by the extraordinary general meeting of the Company to issue the new shares allocated to investors in Tranche 2. To facilitate delivery-versus-payment settlement in the Private Placement, Austur Holding AS has agreed to lend 1,724,097 existing shares in the Company to DNB Carnegie in accordance with a share lending agreement entered into between the Company, DNB Carnegie and Austur Holding AS. Reference is made to the Announcement for further details. Please see the attached notification forms for further information about the transactions by close associates to primary insiders. This information is subject to the disclosure requirements pursuant to MAR article 19 and Section 5-12 the Norwegian Securities Trading Act. For further information, please contact: Roy-Tore Rikardsen, CEO: +354 791 0006 (mobile) Robert Robertsson, CFO: +354 843 0086 (mobile) Attachment PDMR - PP - 5 June 2025
